Several studies have examined the clinical significance of angiogenesis-related biomarkers (VEGF, CD31, CD34, etc.)in osteosarcoma, but their results are at times in conflict and few reports relate to studies with large series. This evidence concerns the gene CD34 and osteosarcoma.